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Pathological RANK signaling in B cells drives
autoimmunity and chronic lymphocytic leukemia
Begüm Alankus1,2*, Veronika Ecker1,2*, Nathalie Vahl1, Martina Braun1,2, Wilko Weichert3,4, Stephan Macher-Göppinger5,
Torben Gehring1, Tanja Neumayer1,2, Thorsten Zenz6, Maike Buchner1,2,4**, and Jürgen Ruland1,2,4,7**
Clinical evidence suggests alterations in receptor activator of NF-κB (RANK) signaling are key contributors to B cell
autoimmunity and malignancy, but the pathophysiological consequences of aberrant B cell–intrinsic RANK signaling remain
unknown. We generated mice that express a human lymphoma–derived, hyperactive RANKK240E variant in B lymphocytes
in vivo. Forced RANK signaling disrupted B cell tolerance and induced a fully penetrant systemic lupus erythematosus–like
disease in addition to the development of chronic lymphocytic leukemia (CLL). Importantly, RANKK240E transgenic CLL cells as
well as CLL cells of independent murine and of human origin depend on microenvironmental RANK ligand (RANKL) for tumor
cell survival. Consequently, inhibition of the RANKL–RANK axis with anti-RANKL antibodies killed murine and human CLL cells
in vitro and in vivo. These results establish pathological B cell–intrinsic RANK signaling as a potential driver of autoimmunity
and B cell malignancy, and they suggest the exploitation of clinically available anti-RANKL compounds for CLL treatment.
Introduction
B lymphocytes are critical for adaptive immunity and host
protection against infection (LeBien and Tedder, 2008), but
when dysregulated they can also drive autoimmunity or develop
into malignant lymphomas (Goodnow, 2007; Kwak et al., 2019;
Nemazee, 2017; Nogai et al., 2011; Taher et al., 2017). The normal
development of B cells in the bone marrow and their activation
and expansion in the periphery are controlled by signals from
the B cell antigen receptor (BCR; Kurosaki et al., 2010; Taher
et al., 2017). Additional signals from dedicated coreceptors are
required to mobilize productive immunity, since B cell engage-
ment by antigen alone has only a limited capacity to activate the
crucial PI3K/AKT and NF-κB pathways for lymphocyte growth
and survival. Instead, BCR engagement alone induces inhibitory
feedback mechanisms that result in B cell anergy, which is one
mechanism that prevents autoreactive B cell activation after
self-antigen sensing. Additional tolerance checkpoints during
B cell differentiation further prevent self-reactive B cell activity
by restricting BCR signaling to the prosurvival factors PI3K/
AKT, NF-κB, and BCL-2 in immature cells (reviewed in
Goodnow, 2007). Pathological mechanisms that disrupt or
overwrite these tolerance checkpoints can result in severely
debilitating autoimmune diseases such as systemic lupus ery-
thematosus (SLE), rheumatoid arthritis (RA), and Sjogren’s
syndrome (reviewed in Goodnow, 2007). Additionally, large
epidemiological studies have demonstrated an increased inci-
dence of B cell malignancies in patients with such autoimmune
conditions (Bernatsky et al., 2006). While these data suggest
that the molecular pathways that drive B cell autoimmunity
and B cell lymphoma overlap, the underlying molecular
mechanisms are still insufficiently defined.
Members of the TNF receptor superfamily (TNFRSF) con-
stitute a family of B cell coreceptors that synergize with the BCR
to enhance clonal lymphocyte proliferation and survival for
the host defenses (Rickert et al., 2011). Prominent examples
are CD40 and B cell–activating receptor. Loss-of-function
mutations in these molecules are causally connected to im-
munodeficiencies in mouse models and humans, and gain-of-
function alterations are associated with autoimmunity and B cell
malignancy (Batten et al., 2004; Rickert et al., 2011; Smulski and
Eibel, 2018). An additional TNFRSF member with emerging po-
tential roles in B cell immunopathology is the receptor activator
of NF-κB (RANK; also designated TNFRSF11A). RANK expression
can be induced on B lymphocytes (Anderson et al., 1997; Yun
et al., 1998) but is also expressed on other cell types, such as
osteoclast precursors and mature osteoclasts or mammary
epithelial cells (Walsh and Choi, 2014). RANK activation by
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cell-bound or soluble forms of RANK ligand (RANKL, also
designated TNFSF11) induces receptor trimerization and,
similar to other TNFRSF members, recruits TNF receptor–
associated factors with activation of PI3K and MAP kinases as
well as canonical and noncanonical NF-κB signaling (Kim
et al., 2009; Wada et al., 2006; Walsh and Choi, 2014).
Systemically increased active levels of RANKL are detected in
the sera of SLE patients, and increased local concentrations are
found in the synovial joint fluids of RA patients, both of which
are positively correlated with disease severity (Carmona-
Fernandes et al., 2011; Fonseca et al., 2005). In addition,
single-nucleotide polymorphisms in either the TNFRSF11A locus
(encoding RANK) or the TNFSF11 locus (encoding RANKL) are
associated with the autoimmune syndromes myasthenia gravis
and autoimmune vitiligo, respectively (Jin et al., 2016; Renton
et al., 2015). Furthermore, the malignant B cells in Hodgkin’s
lymphoma frequently coexpress RANK and RANKL, which are
thought to mediate autocrine or paracrine survival signaling,
and chronic lymphocytic leukemia (CLL) B cells have been re-
ported to express RANK at increased levels compared with
normal B cells (Schmiedel et al., 2013; Secchiero et al., 2006;
Wierda et al., 2003). A possible role of RANK in bone remodeling
was suggested in CLL (Marini et al., 2017). Finally, somatically
acquired mutations in the intracellular signaling domain of
RANK (change of Lys to Glu at amino acid position 240; K240E)
are recurrently detected in human diffuse large B cell lymphoma
specimens (Compagno et al., 2009; Davis et al., 2010; Wilson
et al., 2015), and these mutations have been suggested to lead
to gain-of-function modifications (Davis et al., 2010). While all
these correlative clinical data together indicate that alterations
in the RANKL–RANK signaling axis may contribute to B cell
autoimmunity and malignancy, the pathophysiological con-
sequences of deregulated RANK signaling in B cells remain
unknown.
To study forced RANK signaling in B cells in vivo, we con-
ditionally expressed a human lymphoma–derived RANKK240E
variant in mice. Surprisingly, we found that B cell–intrinsic
RANKK240E signaling was sufficient to drive a fully penetrant
SLE-like autoimmune disease and facilitated B cell transforma-
tion and CLL development, and the tumor cells depended on
RANKL from the microenvironment. The RANKL–RANK axis
also promoted tumor viability in human CLL models and pri-
mary patient samples, which could be disrupted with clinically
available anti-RANKL antibodies.
Results
RANKK240E expression induces ligand-dependent B cell
activation with B1 cell expansion
To study pathological RANK signaling in B cells in vivo, we first
explored whether the human lymphoma–derived RANKK240E
variant (Davis et al., 2010) could be used as a tool inmurine cells.
To this end, we transduced RANKK240E andwild-type (wt) RANK
into the murine Bal17 B cell line (Fig. 1 A). Both wt RANK and
RANKK240E were expressed at the same level and were not
sufficient by themselves to induce B cell activation, as deter-
mined by the expression of the B cell activation markers CD80
and MHCII. Upon exogenous RANKL stimulation, both RANK
variants triggered B cell activation, but RANKK240E-expressing
Bal17 cells exhibited a substantially stronger increase in CD80
and MHCII expression than wt RANK-expressing cells (Fig. 1 B),
indicating hyperactivity of the RANKK240E version. Encouraged
by these results, we next created a transgenic mouse line for
inducible RANKK240E expression by introducing the human
RANKK240E cDNA preceded by a loxP-flanked transcriptional
and translational STOP cassette into the ubiquitously ex-
pressed Rosa26 locus (Pechloff et al., 2010). The resulting
Rosa26loxSTOPloxRANKK240E mice were crossed with CD19-Cre
transgenic animals for B cell–specific excision of the STOP
cassette (Rickert et al., 1997), leading to B cell–restricted
RANKK240E expression. Enhanced GFP is coexpressed with
RANKK240E from an internal ribosomal entry site (IRES) in
double transgenic offspring (referred to as RANKK240E CD19-Cre
mice), which enables monitoring of the RANKK240E-expressing
cells (Fig. S1, A–D).
In the bone marrow of 6–12-wk-old RANKK240E CD19Cre mice,
we detected a regular composition of early pro–, pre–, immature,
and recirculating B cell populations (Fig. S2 A). The percentage
of B220+AA4.1+ immature B cells was comparable to that of lit-
termate control mice, but the RANKK240E-expressing B cells
showed aberrant surface expression of MHCII and CD86, indi-
cating active RANKK240E signaling (Fig. 1 C). In the periphery, we
observed elevated numbers of RANKK240E-expressing B cells in
the spleens (∼2-fold), lymph nodes (∼10-fold), and peritoneal
cavities (∼8-fold; Fig. 1 D), with an activated phenotype char-
acterized by a larger cell size and elevated CD80 and CD86
surface expression and confirmed GFP expression (Fig. 1, E–G).
While the numbers of follicular and marginal zone
B cells were not altered in RANKK240E mice (Fig. S2 B), the
B220lowCD138hi plasma cell population was significantly in-
creased (Fig. 2, A and B), as was the frequency of splenic and
peritoneal CD19+B220low B1 cells (Fig. 2, C–F). These B1 cells
were predominately of the CD5+ B1a subtype (Fig. 2, G and H).
The frequencies and numbers of naive, memory, and central
memory CD4+ and CD8+ T cells were not altered (Fig. S2 C).
Thus, experimentally enforced B cell intrinsic RANKK240E ex-
pression drives premature B cell activation with an accumu-
lation of plasma cells and B1a cells in vivo. In line with these
findings, we also observed an increase in the total concen-
trations of IgA, IgM, IgG2b, and IgG3 in the sera of 3-mo-old
RANKK240E CD19-Cre mice (Fig. 2 I).
RANKK240E expression in B cells drives lymphoproliferative
autoimmune disease
Next, we followed a cohort of RANKK240E CD19-Cremice over time.
Intriguingly, all animals developed fatal lymphoproliferative
disease (Fig. 3 A) with splenomegaly, lymphadenopathy (Fig. 3, B
and C), and pathological lymphocyte infiltration into organs
such as the lungs and kidneys, leading to a disruption of normal
tissue architecture (Fig. 3 D). The expanded B cells were of
polyclonal origin (Fig. 3 E) and showed a two- to threefold in-
crease in the mutation frequency of their variable heavy (VH)
region compared with littermate control B cells, indicating that
they had undergone somatic hypermutations (SHMs; Fig. 3 F).
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Furthermore, indirect immunofluorescence assays using HEp-2
cells indicated the presence of autoreactive antibodies in the
sera of RANKK240E CD19-Cremice (Fig. 3 G). Similarly, we detected
high concentrations of autoimmune antinuclear antibodies
(ANAs) against single- and double-stranded DNA by ELISA
(Fig. 3 H). Finally, we found mesangial and subendothelial
immune-complex depositions in the kidneys (Fig. 3 I) and mas-
sive proteinuria as a sign of kidney damage in RANKK240E CD19-Cre
mice but not in control littermate mice (Fig. 3 J). Thus, patho-
logical RANKK240E signaling in B cells disrupts immune tolerance
Figure 1. Effects of RANKK240E expression on B cells in vitro and in vivo. Bal17 cells were infected with retroviruses to express empty vector (GFP), RANK
wt, and RANKK240E and sorted for GFP+ cells. (A) The surface RANK expression in Bal17 cells transduced with wt RANK or RANKK240Ewas equal as determined
by flow cytometry; representative of two independent experiments. (B) The empty vector (GFP), RANK wt, and RANKK240E-expressing Bal17 cells were
subsequently stimulated with 100 ng/ml RANKL for 1 h. Activated surface marker expression (CD80 and MHCII) was measured using flow cytometry. The
pooled analysis from three independent experiments is shown with a relative increase in the mean fluorescence intensity (MFI) compared with the empty
vector control (GFP). For statistical analysis, Student’s t test was performed. *, P < 0.05. (C) Immature B cell activation upon RANKK240E expression. Cells were
pregated on immature B cells (B220+AA4.1+), and RANKK240E/GFP-expressing cells were distinguished by the expression of GFP. The data shown are rep-
resentative of five independent experiments, with a total number of at least 12 mice analyzed per genotype. (D) Total B cell counts in the spleen, LN, and
peritoneal cavity (PC) as determined by CD19+ lymphocytes; the data shown are representative of three independent experiments, with a total number of at
least six mice analyzed per genotype; dot plot graphs are shown for individual mice, and bars indicate the means with SD; Student’s t test was performed. *, P <
0.05; **, P < 0.01. (E and F) RANKK240E expression mediates an activated B cell phenotype in vivo: CD80, CD86, and forward-scatter area (FSC-A) expression
were measured using flow cytometry of splenic B cells. The data shown are representative of four independent experiments, with a total number of at least
eight mice analyzed per genotype. (G) RANKK240E expression is indicated by GFP expression; representative example for at least n = 30 mice analyzed.
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and promotes the expansion and activation of B cell clones with
high-affinity autoimmune BCRs (Detanico et al., 2013; Guo et al.,
2010), resulting in a systemic autoimmune disorder with key
hallmarks of human SLE, such as ANAs and terminal kidney
damage (Tsokos, 2011).
RANKK240E-expressing B cells use RANKL from the
microenvironment for survival and proliferation
To understand the cellular effects of pathological RANKK240E
signaling in B cells, we next isolated B lymphocytes from
RANKK240E CD19-Cre and littermate control mice and cultured
them in vitro. Even without exogenous stimulation, the
RANKK240E-expressing B lymphocytes survived significantly
better than wt B cells (Fig. 4 A, left), as determined by flow
cytometric analysis. Over five days, B cells of both genotypes
died progressively. However, upon exposure to exogenous
RANKL, the RANKK240E-expressing B cells remained viable for
at least 5 d (Fig. 4 A, center), and they proliferated vigorously in
contrast to wt B cells even without additional mitogens or BCR
costimulation (Fig. 4 B). These growth-promoting effects of
RANKL were neutralized by α-RANKL antibodies (Fig. 4, A and
B), demonstrating that the RANKK240E signals are massively
enhanced by exogenous RANKL stimulation.
Multiple cell types can provide RANKL to developing and
mature B cells in vivo (Walsh and Choi, 2014), most prominently
stromal cells in the bone marrow microenvironment and acti-
vated CD4+ T cells in peripheral tissues (Wang et al., 2002). To
determine whether these cell types could stimulate RANKK240E
transgenic B cells, we first cocultured RANKK240E-expressing B
lymphocytes with stroma-derived ST-2 cells that endogenously
express RANKL (Nishida et al., 2005). In the presence of ST-2
cells, RANKK240E-expressing B cells, though not wt B cells from
littermate control mice, acquired an activated phenotype, as
indicated by CD80 expression. Moreover, their cell size in-
creased, and RANKK240E-expressing B cells proliferated rapidly
(Fig. 4 C). Immunohistochemistry analysis of bonemarrow from
RANKK240E CD19-Cre mice further demonstrated that the bone
marrow microenvironmental cells also strongly expressed
RANKL in vivo in the direct vicinity of RANKK240E-expressing
B cells (Fig. 4 D). Subsequent flow cytometric analysis revealed
that primarily ex vivo isolated CD4+ T cells express RANKL in
RANKK240E CD19-Cre mice (Fig. 4 E and Fig. S3, A and B). In line
with this finding, ex vivo–activated peripheral CD4+ T cells,
which, as expected (Wang et al., 2002), up-regulated RANKL on
the surface (Fig. 4 F), were also able to induce robust and se-
lective activation of RANKK240E-expressing B cells but not wt
B cells from littermate control mice (Fig. 4 G).
To gain mechanistic insights into the intracellular pathways
that mediate the RANKK240E-induced pathological effects, we
then stimulated RANKK240E transgenic B cells with RANKL or
the TLR9 agonist CpG as a control in vitro and performed
Western blot analysis. RANKL stimulation induced the activa-
tion of the JNK and ERK pathways in RANKK240E-expressing
cells but not in wt B cells from littermate control mice (Fig. 4 H).
The PI3K/AKT pathway was also robustly activated (Fig. 4 H).
Overall, JNK, ERK, and AKT activation by RANKL was more
pronounced than that seen upon CpG stimulation in RANKK240E-
expressing B cells, which is consistent with the notion that
RANKK240E is a strong signaling receptor (Fig. 4 H). Pharmaco-
logical inhibition of PI3K or JNK signaling, though not MEK or
NF-κB inhibition, prevented the prosurvival and mitogenic ef-
fects of RANKL (Fig. 4 I and Fig. S3 C) and the activated B cell
phenotype induced by RANKK240E ligation (Fig. S3 D). These
results together indicate that the activation of the PI3K and JNK
pathways is particularly critical for the B cell–intrinsic effects of
forced RANKK240E signaling. To gain further insight into the
effectors of RANKK240E signaling that mediate survival and
proliferation, we analyzed the expression of the antiapoptotic
molecule Bcl-2 and the cell cycle regulator Cyclin-D1. Both factors
are significantly higher expressed in RANKK240E-expressing
B cells as compared with wt B cells from littermate control mice
(Fig. 4 J). In addition, the expression of Pten, a negative regulator
of the PI3K signaling pathway, was significantly reduced in
RANKK240E CD19Cre B cells as compared with wt B cells (Fig. 4 J),
which is in line with the high levels of AKT phosphorylation
observed in RANKK240E-expressing B cells (Fig. 4 H).
RANKK240E expression facilitates CLL development in
aged mice
As indicated above, aberrant RANK signaling is potentially in-
volved not only in autoimmunity but also in the pathogenesis of
human B cell lymphomas. Therefore, we monitored aging
RANKK240E CD19-Cre mice for indications of B cell malignancy.
Intriguingly, in RANKK240E CD19-Cre animals that survived longer
than 12 mo we detected dramatic accumulations of GFP+, CD19+,
and CD5+ B1a cells (Fig. 5 A), which together constituted a ho-
mogeneous population. A PCR-based clonality analysis defining
IgVH D–J joinings of different sizes demonstrated that these
Figure 2. RANKK240E expression mediates B cell differentiation and antibody production. (A) The increased percentage of plasma cells in the spleen of
6-mo-old RANKK240E CD19-Cremice is shown with a representative FACS plot. (B) Summary of the total cell counts of plasma cells in the spleens of 8–12-wk-old
RANKK240E CD19-Cre mice (n = 8) and littermate controls (n = 7) are shown as a dot plot graph with mean + SD indicated. Analysis was performed in five
independent experiments. (C) Representative analysis of B1 and B2 cell populations in the spleen by flow cytometry (6-mo-old animal). (D) Dot plot graph
depicting the absolute B1 cell count in the spleen of 6–12-wk-old RANKK240E CD19-Cre (n = 8) and control (n = 7) mice. Analysis was performed in five independent
experiments. (E) Representative analysis of B1 and B2 cell populations in the peritoneum of 6-mo-old RANKK240E CD19-Cre mice and littermate control by flow
cytometry. (F) Dot plot graph depicting the absolute B1 cell count in the peritoneum of 6–12-wk-old RANKK240E CD19-Cre (n = 8) and control (n = 7) mice. Analysis
was performed in five independent experiments. (G) B1a cell expansion in RANKK240E CD19-Cremice revealed by flow cytometry. The cells were pregated for the
CD19+B220low B1 population, and a representative FACS plot for CD5 expression is shown. (H) Dot plot graph is depicting the relative B1a cell count in the
peritoneum of 6–12-wk-old RANKK240E CD19-Cre (n = 6) and control (n = 3) mice. Analysis was performed in two independent experiments. (I) Basal serum levels
of IgA, IgM, IgG2b, and IgG3 in 3-mo-old mice (n ≥ 5 per genotype); analysis was performed in two independent experiments. The data are shown as the mean
with SEM. For statistical analysis, Student’s t test was performed. *, P < 0.05; **, P < 0.01.
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Figure 3. RANKK240E expression drives disease in vivo. (A) Kaplan–Meier curve of CD19-Cre and RANKK240E CD19-Cremice (n = 22 for RANKK240E CD19-Cremice
and n = 7 for CD19-Cre mice). For statistical analysis, log-rank (Mantel Cox) analysis was performed. ****, P < 0.0001. (B) Macroscopic appearance of
representative spleens and mesenteric lymph nodes (in centimeters), representative example for RANKK240E CD19-Cre and littermate control mice analyzed for n
≥ 5 per genotype. (C) Dot plot graph depicts spleen weight for RANKK240E CD19-Cre (n = 8) and littermate control (n = 5) mice is shown (<6 mo of age).
(D) Representative histological analysis of n ≥ 3 per genotype mice analyzed revealed glomerulonephritis-related kidney destruction and cellular infiltration of
lungs in RANKK240E CD19-Cre mice were revealed by H&E staining (scale bars, 1 mm). (E) Ig clonality analysis by PCR of genomic DNA isolated from GFP+-sorted
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populations originated from single dominant B1 cell clones
(Fig. 5 B). In total, ∼20% of the RANKK240E CD19-Cre mice lived
longer than 12 mo, and we detected these expanded splenic
CD19- and CD5-positive B cell subsets in all of these mice. To test
whether the accumulated B1 cells were oncogenically trans-
formed, we transplanted them into secondary nonirradiated,
immunocompetent wt recipients andmonitored the fate of these
cells over time. In all cases, we observed an engraftment of the
GFP+, CD19+, and CD5+ B1a cells in the secondary hosts and an
accumulation of these cells over time (Fig. 5, C and D), demon-
strating that they had acquired self-renewal capacity, which
together with the clonal origin documents malignant transfor-
mation. Phenotypically, these transformed B1a cells resembled
CLL cells, which characteristically coexpress CD19 and CD5
(Matutes et al., 1994) together with low surface expression of
B220 and IgD (Fig. 5, E and F), and thus also phenocopied the
malignant CLL cells of the classical TCL1-transgenic CLL mouse
model (Fig. 5 F; Bichi et al., 2002). In addition, upon trans-
plantation to secondary wt recipients, the transformed
RANKK240E-expressing B1 cells accumulated in the blood, the
spleen, and the peritoneal cavity and to a lesser extent in the
bone marrow of wt recipients (Fig. 5 G) and thereby resemble
the phenotypic behavior of adoptively transferred classical
TCL1-transgenic CLLs (Hofbauer et al., 2011). To test whether the
transformed RANKK240E-expressing CLL cells would still re-
spond to exogenous RANKL, we then stimulated them with the
ligand. Indeed, RANKL still provided a strong survival signal to
these transformed CLL cells, which was blocked by a neutral-
izing anti-RANKL antibody (Fig. 5 H). Thus, chronically en-
forced RANK signaling within B cells facilitates CLL
development, and the presence of exogenous RANKL is contin-
uously required to maintain the survival of RANKK240E-ex-
pressing tumor cells.
Murine and human CLL cell survival depends on RANK–RANKL
signaling
Because the crosstalk between malignant B cells and accessory
cells in the microenvironment is of general importance for CLL
tumor cell growth and disease progression (Burger, 2013), we
next explored the role of RANKL–RANK signaling on a CLL
background without the RANKK240E transgene. To this end, we
first studied RANK receptor expression on CLL cells from TCL1
transgenic mice (Bichi et al., 2002) and found that these ma-
lignant cells expressed high levels of RANK on their surface,
with a mean 10-fold increase compared with peripheral wt
CD19+ B cells from littermate control mice (Fig. 6 A). Subse-
quently, we cocultured CLL cells from six individual TCL1
transgenic mice with ST-2 stromal cells in the presence or ab-
sence of anti-RANKL antibodies. The ST-2 stroma strongly
supported the viability of the CLL cells, and the addition of anti-
RANKL significantly reduced this survival signal, indicating that
supportive stroma effects are at least in part mediated via the
RANKL–RANK axis (Fig. 6 B). Next, we treated a cohort of mice
with TCL1 transgenic CLL with anti-RANKL antibodies. After 4
wk of treatment with the blocking RANKL antibody, we detected
a significantly lower leukemia cell burden in the spleens and the
bone marrow than that in the vehicle control (Fig. 6 C), which
demonstrates that the RANKL–RANK axis contributes to the
leukemia-supportive CLL microenvironmental crosstalk in vivo.
To explore the relevance of these findings in human CLL
models, we then xenotransplanted the human MEC-1 CLL cell
line into immunocompromised NOD/SCID/IL2rγ−/− (NSG) mice
and treated these animals with anti-RANKL antibodies. RANK
expression on MEC-1 cells was confirmed and significantly up-
regulated upon contact with ST-2 stromal cell (Fig. 6 D).
Whereas all animals of the control group had to be euthanized
24 d after MEC-1 transplantation because of weight loss and hind
limb paralysis due to infiltration of the MEC-1 cells into the
spinal cord (Fig. 6 E), anti-RANKL treatment significantly ex-
tended the symptom-free survival for this aggressive, rapidly
progressing human CLL xenograft model (Bertilaccio et al.,
2013). Then, we investigated the supportive effects of the
RANKL–RANK axis on primary CLL patient samples by incu-
bating themwith and without ST-2 stromal cells in the presence
and absence of anti-RANKL. The CLL patient characteristics are
shown in Table S1. Strikingly, while the ST-2 stromal cells
supported the viability of the primary CLL cells, this supportive
effect was largely abrogated by the anti-RANKL treatment
(Fig. 6 F). Altogether, these results demonstrate that the
RANKL–RANK signaling axis provides general microenviron-
mental survival support for both murine and human CLL cells
in vitro and in vivo and that this leukemia-promoting signal can
be disrupted using anti-RANKL antibodies.
Discussion
In this study, we forced RANKK240E expression in B cells to ex-
perimentally explore the consequences of aberrant RANK sig-
naling in B cell immunopathology. The RANKK240E receptor
triggers potent cell survival and proliferation pathways in B
B cells, representative of seven mice (6 mo of age) per genotype. (F) SHM analysis of 4-mo-old mice by PCR of genomic DNA isolated from GFP+-sorted B cells
derived from four mice per genotype, revealing a significantly increased mutation frequency in RANKK240E CD19-Cre mice. Fragments corresponding to the
VHJ558-JH4 region were amplified and sequenced, and the mutation rate of the V region (∼300 bp) was determined by IMGT analysis. (G) Detection of high
levels of antinuclear IgG in RANKK240E CD19-Cre mice. Autoreactive antibodies in sera of CD19-Cre and RANKK240E CD19-Cre mice (>3 mo of age) using HEp-2 cells
were detected by indirect immunofluorescence. Secondary detection antibodies were labeled with FITC (anti-IgG) or APC (anti-IgM). Representative example is
shown for n = 4 per genotype, analyzed in two independent experiments. Scale bars, 25 µm. (H) Basal serum levels of total ANAs, anti-ssDNA (single-strand
DNA) antibodies, and anti-dsDNA (double-strand DNA) antibodies in 6-mo-old mice (n ≥ 4 per genotype), analyzed using Alpha Diagnostic International
Autoimmune ELISA kits in two independent experiments. (I) Scanning electron microscopy images of kidneys in terminally ill 6-mo-old RANKK240E CD19-Cremice
showing massive electron-dense (immune) deposit accumulation (indicated by arrowheads, representative of three mice; scale bars, 3 µm). (J) Kidney de-
struction in RANKK240E CD19-Cre mice is also evident in the increased proteinuria (n = 6 per genotype). The data shown were obtained from terminally ill 6-mo-
old animals. For statistical analysis, Student’s t test was performed. **, P < 0.01; ***, P < 0.001.
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lymphocytes in vitro and disrupts B cell tolerance in vivo, re-
sulting in fully penetrant SLE-like autoimmunity with pro-
gression to B cell malignancy.
The pathological effect of the RANKK240E receptor in B cells
depends on the presence of exogenous RANKL, as these effects
are inhibited by anti-RANKL treatment. In vivo, RANKL can be
secreted by the bone marrow microenvironment and by acti-
vated T cells to stimulate RANKK240E transgenic B cells. Our
analyses show that wt B cells do not exhibit enhanced survival
nor proliferation upon exposure to RANKL in culture, which is
consistent with the fact that B cells that are conditionally defi-
cient for RANK do not show a strong phenotype (Perlot and
Penninger, 2012). However, stimulation of RANKK240E by its
ligand triggers strong activation of PI3K and JNK signaling in
RANKK240E-expressing B cells. In line with this, inhibition of
PI3K or JNK signaling prevented RANKL-mediated B cell acti-
vation and survival of RANKK240E-expressing B cells. The in-
duction of PI3K signaling upon RANK ligation can occur directly
via recruitment of TNF receptor–associated factors and activa-
tion of c-Src (Arron et al., 2001; Wong et al., 1999), while the
repression of Pten that we observed may additionally contribute
to sustaining PI3K signaling in RANKK240E-expressing B cells.
Together, these data demonstrate that the PI3K pathway and the
JNK pathway are dominant RANKK240E effector cascades.
In vivo, chronic RANKK240E signaling resulted in the expan-
sion of B cells, particularly of the B1 subset, and in the loss of
self-tolerance with an altered repertoire, which is demonstrated
by the presence of serum autoantibodies and the autoimmune
pathology in RANKK240E CD19-Cre mice. Consistent with the hy-
pothesis that these pathologies are also driven by aberrant PI3K
signaling, similar phenotypes have previously been observed in
other mouse models with enhanced PI3K activity (Anzelon et al.,
2003; Suzuki et al., 2003). Downstream of PI3K activation,
FOXO factors are inactivated in developing B cells (Fruman and
Bismuth, 2009; Zhang et al., 2011). Therefore, RANK-mediated
PI3K activation at B cell selection checkpoints could in theory
prevent proper FOXO-mediated induction of the proapoptotic
molecule Bim, which results in the survival of autoreactive
B cells (Arron et al., 2001; Enders et al., 2003; Lau et al., 2020;
Wong et al., 1999). This is likely one mechanism bywhich forced
RANKK240E signaling can disrupt B cell tolerance. In addition,
RANK is also a strong activator of NF-κB (Anderson et al., 1997).
We did not detect significant reduction of RANKK204E-mediated
B cell survival using an NF-κB inhibitor nor substantial NF-κB
activity in ex vivo–stimulated RANKK204E-expressing B cells (not
shown), likely due to feedback regulation upon prolonged
RANKK204E activation (Ruland, 2011). Nevertheless, it is con-
ceivable that pulsed RANKK204E-mediated NF-κB activity in vivo
could enhance cell survival and proliferation in vivo and con-
tribute to the loss of B cell tolerance in RANKK240E transgenic
mice (Grossmann et al., 2000; Guttridge et al., 1999; Hinz et al.,
1999).
Our experimental strategy for B cell–specific RANKK240E
expression used the CD19-Cre transgene to induce RANKK240E at
the pre–B cell stage and throughout further development
(Rickert et al., 1997). Normal developing B cells typically express
only very low levels of RANK at this stage (https://www.imm-
gen.org and our ownmRNA analysis; data not shown). However,
RANK can be induced on B lymphocytes, for example, by acti-
vated CD40L-expressing T cells (Yun et al., 1998). Therefore, it is
possible that pathological RANK expression on individual hu-
man autoreactive B lymphocyte clones could mediate their
survival upon RANKL binding and thereby disrupt central or
peripheral immune tolerance and promote autoimmune disease.
This hypothesis warrants further investigation but would be in
line with the high levels of free RANKL in human SLE and RA
patients (Carmona-Fernandes et al., 2011; Fonseca et al., 2005).
Moreover, a recent study using murine RA models reported
progressively increased RANKL levels in the diseased mice,
which positively correlated with disease severity (Papadaki
et al., 2019). While the genetic inactivation of RANKL dramati-
cally attenuated arthritis, the overexpression of RANKL exac-
erbated RA in these animals (Papadaki et al., 2019). Since the
RANKL–RANK axis is key for physiological bone remodeling and
bone regeneration during inflammatory diseases, several effects
of RANKL in RA mice are presumably due to the stimulation of
osteoclasts. However, based on our results that demonstrate
that pathological B cell–intrinsic RANK signaling can promote
Figure 4. RANKK240E-expressing B cells are dependent on RANKL for survival and proliferation in vitro. (A and B) GFP+-sorted B cells from 2–4-mo-old
RANKK240E CD19-Cre and CD19-Cre control mice were stained with CellTrace Violet proliferation dye and kept in culture in the presence or absence of RANKL or
α-RANKL for 5 d. Flow cytometry analysis of Annexin V– and 7-AAD–stained B cells revealed enhanced survival and proliferation in the presence of RANKL. The
viability was normalized to d0 (defined as 100%) for each individual mouse. The data shown are representative of four independent experiments with a total of
eight mice per genotype. (C) GFP+-sorted B cells from 2–4-mo-old RANKK240E CD19-Cre and CD19-Cre control mice were stained with CellTrace Violet pro-
liferation dye, incubated with ST-2 bone marrow stromal cells for 72 h in culture, and analyzed for CD80 as a B cell activation marker, cell size, and cell
proliferation by flow cytometry. The data shown are representative of three independent experiments with at least six mice per genotype. (D) Immuno-
histochemistry staining of bone marrow from 4-mo-old RANKK240E CD19-Cre mice showing RANKL+ bone marrow stromal cells in RANKK240E CD19-Cre mice.
(E) RANKL surface expression was detected on CD45+CD4+ T cells in RANKK240E CD19-Cre mice as compared with isotype control (anti-mouse IgG2a) staining.
Representative analysis for a total of n = 5 mice is shown (summary for spleen and bone marrow depicted in Fig. S3, A and B). (F)MACS-isolated, CD3/CD28-
activated CD4+ T cells were analyzed for RANKL surface expression by flow cytometry, and a representative example of three independent experiments is
shown at 24 h after stimulation. (G) GFP+-sorted B cells from 2–4-mo-old RANKK240E CD19-Cre and CD19-Cre control mice were incubated with magnetic bead-
isolated, CD3/CD28-activated CD4+ T cells for 48 h and analyzed for CD80 and MHCII activation markers by flow cytometry (representative for n = 3 per
genotype). (H) Immunoblots of GFP+-sorted B cells from the spleens of 4-mo-old mice. The data shown are representative of at least two independent
experiments. (I) Pharmacological inhibition of the JNK pathway with SP600125 and the PI3K pathway with Cal-101 24 h after stimulation with RANKL led to
drastically reduced cell survival in RANKK240E-expressing B cells (n ≥ 4 mice analyzed in two independent experiments). (J) Transcriptional expression levels of
Bcl-2, Cyclin-D1, and Pten in sorted B cells of 2–4-mo-old RANKK240E CD19-Cre and CD19-Cre littermate control mice (n ≥ 7 per genotype, determined in three
independent experiments). For statistical analysis, Student’s t test was performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 5. Aged RANKK240E-expressing mice develop CLL. (A) Flow cytometric analysis of splenocytes harvested from 12-mo-old RANKK240E CD19-Cre mice
revealed 74% CD19+CD5+ cells. GFP expression was confirmed. Representative for six >12-mo-old RANKK240E CD19-Cremice analyzed. (B) Ig clonality analysis of
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immunopathology, investigating additional effects of anti-
RANKL treatment on B lymphocytes is important in RA mod-
els and in human autoreactive B cell responses. This is of
particular interest, as the RANKL–RANK axis can be efficiently
targeted in the clinic with the blocking anti-RANKL antibody
denosumab, which is routinely used for the treatment of oste-
oporosis or osteolytic bone metastasis (Cummings et al., 2009;
Henry et al., 2014) and is currently under investigation for RA
treatment (Takeuchi et al., 2019).
In addition to autoimmunity, prolonged B cell–intrinsic
RANKK240E signaling promotes the development of B cell
malignancy over time that resembles human B cell lymphoma
and CLL and phenocopies classical CLL mouse models with
characteristic surface marker expression and in vivo growth
patterns (Bichi et al., 2002). This specific clonal CLL phenotype
of ourmodel exhibits self-renewal capacity, which is presumably
facilitated by an initial RANKK240E-driven expression of survival
and proliferation genes such as Bcl-2 or Cyclin-D1 and an ex-
pansion of tolerized B1 cells that represent the CLL progenitor
population (Hayakawa et al., 2016). CLL cells frequently recog-
nize autoantigens (Dühren-von Minden et al., 2012; Hamblin
et al., 1999; Iacovelli et al., 2015), and their pathological BCR
genomic DNA isolated from total peripheral blood of wt mice transplanted with splenocytes from an aged RANKK240E CD19-Cre mouse, representative for three
>12-mo-old RANKK240E CD19-Cremice analyzed. Tx, transplantation. reTx, retransplantation. (C) After transplantation of 2 × 10e7 splenocytes into wt recipients,
the percentages of GFP+ and CD19+CD5+ cells were detected in the peripheral blood via regular blood draws. The engraftment of one of three different
RANKK240E CD19-Cre donor mice is shown. (D) Summary of percent CLL cells from three donors in the peripheral blood (PB) of four wt recipients, 3 mo after
transplantation (Tx). (E) MFI values of B220 and IgD from three independent donors of RANKK240E-derived CLL cells in different wt recipients are shown. For
statistical analysis, Student’s t test with paired analysis was performed; ***, P < 0.001. (F) CLL phenotypic analysis was performed in wt mice transplanted
with cells from RANKK240E CD19-Cre mice (representative for n = 5) and compared with that of classical TCL1-driven CLL (representative for n = 3). GFP ex-
pression was confirmed in the transplanted RANKK240E transgenic CLL cells. (G) Organ distribution of CD19+CD5+ RANKK240E transgenic cells in wt mice upon
transplantation is shown; representative example for four recipient mice analyzed. (H) In vitro survival at day 10 in culture of CLL cells derived from an aged
RANKK240E CD19-Cre mouse in the presence and absence of RANKL and simultaneous RANKL blocking antibodies; representative for three independent ex-
periments using two individual donor CLL from RANKK240E CD19-Cre mice.
Figure 6. RANK–RANKL is an important survival axis for CLL cells within their microenvironment. (A) TheMFI values of RANK expression on the surface
of CD19+ WT B cells and CD19+CD5+murine CLL cells derived from TCL1 transgenic aged mice (n = 5, measured in three independent experiments) are shown.
(B) In vitro survival of murine CLL cells derived from five TCL1 transgenic donor mice in the presence and absence of the RANKL-expressing stromal cell line
ST-2 with concomitant RANKL blocking antibody is shown, measured in two independent experiments. (C) Splenocytes and bone marrow cells were analyzed
for CLL cell content after transplantation of TCL1-tg CLL into 10 wt recipients and administration of the RANKL blocking antibody twice a week (n = 5) or
control (PBS, n = 5) for a total of 4 wk. (D) Surface RANK expression onMEC-1 cells was confirmed by flow cytometry with and without stromal cell contact for
24 h. Representative FACS analysis for three independent experiments is shown. (E) The CLL-derived MEC-1 cell line was transplanted into 10 NSG mice, and
on day 8, RANKL treatment (n = 5) or control treatment (n = 5) was initiated twice a week. Kaplan-Meier analysis is shown, and for statistical analysis, log-rank
(Mantel Cox) analysis was performed. ****, P < 0.0001. (F)Human patient–derived CLL cells derived from 12 individual donors were cocultured with the RANKL-
expressing stromal cell line ST-2 in the presence and absence of RANKL blocking antibody. Viability was assessed in three independent experiments by DAPI
exclusion via flow cytometry. For statistical analysis, Student’s t test was performed unless indicated otherwise. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
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signals are indispensable for CLL development (Hayakawa et al.,
2016). Under normal conditions, autoreactive BCR signaling
triggers negative selection and deletion of the specific B cell clone
(Hartley et al., 1991; Köhler et al., 2008). As pathological
RANKK240E signaling can overcome negative selection, these
enforced survival signals are likely to support the growth of
premalignant autoreactive B1 cells and thereby enable these cells
to acquire additional genetic alterations leading to malignant
transformation. RANK with its agonistic ligand RANKL induces
the activation of B cell survival pathways in these cells. In ad-
dition, RANKK240E was originally identified from human diffuse
large B cell lymphoma, which typically originates from germinal
center B cells (Küppers et al., 1999). It is thus conceivable that
aberrant RANK signaling could also facilitate B cell malignancies
at other developmental stages, and it is therefore important to
explore the consequences of forced RANK expression selectively
in B cells beyond the B1 stage in vivo.
In CLL, it is well established that the survival and expansion
of tumor cells depends critically on close microenvironmental
interactions with bystander cells (Burger, 2013). We have now
identified the RANKL–RANK interaction as an important mi-
croenvironmental signal that promotes CLL development and
CLL cell survival in the murine and human systems. High levels
of RANK receptor are detected on the surface of human
patient–derived CLL cells and on murine CLL cells (Schmiedel
et al., 2013; Secchiero et al., 2006). Blocking anti-RANKL anti-
bodies, which disrupt the RANKL–RANK interaction, thereby
prevents prosurvival programs, inhibiting not only the survival
of RANKK240E transgenic CLL cells, but also TCL1 transgenic CLL
cells, human CLL cell lines, and primary patient samples both
in vitro and in vivo. Together, our findings not only demonstrate
that aberrant RANK signaling contributes to the development of
CLL in the early phases and upon experimental RANKK240E
transgene expression but also show that pathological RANKL–
RANK signals mediate CLL tumor cell maintenance after ma-
lignant B cell transformation in a broader context. Together with
the clinical availability of the blocking anti-RANKL antibody
denosumab, our results warrant translational investigations
targeting the RANKL–RANK axis for CLL treatment. Since mi-
croenvironmental up-regulation of prosurvival factors also
contributes to the resistance of CLL cells to current drug ther-
apies (Leverson and Cojocari, 2018; Munk Pedersen and Reed,
2004), the potential effects of anti-RANKL in counteracting
chemoresistance or targeted therapy resistance should also be
investigated.
In conclusion, our study provides mechanistic insights into
the functions of aberrantly enforced RANK signaling in B cell–
mediated autoimmunity and CLL pathogenesis. The codevelop-
ment of these B cell pathologies in RANKK240E transgenic mice is
in line with the strong epidemiological link between human CLL
and autoimmune manifestations (Barcellini et al., 2006; Duek
et al., 2006; Vanura et al., 2008). These results indicate that
aberrant RANKL–RANK signaling is a potential common mech-
anism of these pathologies. Our data further encourage explor-
ing the potential of repurposing clinically available compounds
that target the RANKL–RANK axis for the treatment of B cell–
mediated autoimmunity and malignancies.
Materials and methods
Mice
Human RANKK240E cDNA was cloned into the ubiquitously ex-
pressed ROSA26 vector, preceded by a loxP-flanked tran-
scriptional and translational STOP cassette. ROSA26 was
subsequently linearized and electroporated into 129Ola em-
bryonic stem cells. The clones were verified by Southern blot
analysis with a 59 flanking ROSA26 probe and specific PCR, as
previously described (Knies et al., 2015). Blastocyst injection of
the clones and subsequent chimera breeding resulted in
RANKK240E stopFL mice, which were then crossed with CD19-Cre
mice (Rickert et al., 1997). The bicistronic expression of
RANKK240E together with enhanced GFP preceded by an IRES
sequence allowed monitoring of RANKK240E-expressing cells
via fluorescence. Mice were backcrossed to C57/Bl6 mice for at
least six generations, and littermates were used as controls in
all experiments. The TCL1 transgenic mouse model (Bichi et al.,
2002) was used to compare RANKK240E-derived leukemic cells
and to study the effects of anti-RANKL treatment in an in vivo
CLL transplantation setting. For murine transplantation ex-
periments, recipient mice were ordered from Janvier Labs
(C57/Bl6/N). For xenotransplant experiments, we used NSG
mice (NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ; purchased from Jackson
Laboratories) as recipients for the human MEC-1 CLL-like cell
line (purchased from Deutsche Sammlung von Mikroorganis-
men und Zellkulturen (DSMZ)). All animal work was con-
ducted in accordance with German Federal Animal Protection
Laws and approved by the Institutional Animal Care and Use
Committee at the Technical University of Munich.
Cell culture
The mature murine B cell lymphoma cell line Bal17 (RRID:
CVCL_9474), freshly isolated primary B cells, isolated primary
TCL1 transgenic CLL cells, and CD4+ T cells were cultured in
RPMI-1640 medium supplemented with 10% FBS, 1% penicillin/
streptomycin, 1% L-glutamine, and 0.1% 2-mercaptoethanol.
ST-2 mouse bone marrow stromal cells and Phoenix-E and
HEK293FT packaging cells were kept in DMEM supplemented as
described above. Primary CLL patient–derived cells were cul-
tured in RPMI-1640 Glutamax medium containing 10% FBS, 1%
penicillin/streptomycin, 1% sodium butyrate, and 1% nonessen-
tial amino acids. The CLL-like MEC-1 cell line was cultured in
IMDM supplemented with 10% FBS and 1% penicillin/strepto-
mycin. All cells were cultured under standard cell culture con-
ditions at 37°C in 5% CO2 and 95% humidity.
Retroviral transduction
Human RANKK240E and wt RANK were cloned into a pMSCV-
IRES-GFP vector (Addgene plasmid # 27490; RRID: Addg-
ene_27490) using standard techniques. Viral supernatants were
produced by infecting Phoenix-E packaging cells as previously
described (Knies et al., 2015). Bal17 cells were transduced with
the viral supernatant by spin infection.
Measurement of serum Ig and autoantibody levels
Detection of serum Ig was performed using the Mouse Immu-
noglobulin Panel, manufactured by Southern Biotech, using
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diluted sera as previously described (Knies et al., 2015). Detec-
tion of serum autoantibodies was performed according to the
manufacturer’s instructions using Autoimmune ELISA Kits
manufactured by Alpha Diagnostic International. Sera were di-
luted before use.
Flow cytometry and FACS
Organs were processed into single-cell suspensions, treated with
red blood cell lysis buffer, and resuspended and washed in FACS
buffer (PBS, 3% FBS). After incubation with CD16/32 to block
free Fc receptors, the cells were washed in FACS buffer again and
incubated for 20 min at 4°C with fluorescently conjugated an-
tibodies against surfacemolecules. All antibodies were diluted in
FACS buffer. The cells were acquired using a FACS CantoII flow
cytometer (BD), and the results were analyzed using FlowJo
Software (Tree Star, Inc.). The following antibodies were used:
B220 (RA3-6B2), CD80 (16-1QA1), CD86 (GL1), IgM (II/41), IgD
(11-26c), CD19 (1D3), MHCII (M5/114.15.2), CD138 (281–2), CD4
(GK1.5), CD5 (53–7.3), CD8 (53–6.7), CD44 (IM7), CD62L (MEK-14),
CD93 (AA4.1), RANK (CD265, 9A725; ThermoFisher Scientific),
and RANKL (CD254, IK22/5; all from eBioscience unless stated
otherwise). RANKK240E-expressing B cells were sorted for GFP+
cells for downstream applications. CD19-Cre B cells were stained
with CD19 and sorted for CD19+ cells. Cells were sorted directly
into filtered sterile FBS and washed with FACS buffer before use.
Cell viability was quantified by flow cytometry with Annexin V
and 7-AAD staining or DAPI (eBioscience), and cell proliferation
was quantified by CellTrace Violet Cell Proliferation Kit (Ther-
moFisher Scientific) staining.
Electron microscopy
Kidney biopsies were fixed for at least 2 h with 3% glutaralde-
hyde in Sörensen’s buffer, pH 7.4, washed three times in
Sörensen’s buffer, post-fixed for 1 h in 1% osmium tetroxide,
washed three times in Sörensen’s buffer, dehydrated by a graded
series of ethanol, transferred into propylene oxide, and em-
bedded in epon-araldite. Semithin and 70–80-nm ultrathin
sections were cut with a Reichert Ultracut E ultramicrotome,
counterstained with uranyl acetate and lead citrate, and exam-
ined with a JEOL 1400 transmission electron microscope
equipped with a TVIPS F216 digital camera.
Ig clonality and SHM assays
The clonality of the B cell repertoire in mice was determined
using genomic DNA isolated from sorted B cells by PCR as de-
scribed previously (Pennycook et al., 1993). SHM frequency was
detected via a nested PCRmethod as previously described with a
set of 59 consensus primers for murine VH or D segments of the
heavy chain regions (Ehlich et al., 1994), followed by subcloning
and sequencing of the amplified segments. The sequencing re-
sults were analyzed using the international ImMunoGeneTics
information system (IMGT)/V-QUEST database.
Indirect immunofluorescence HEp-2 assay
Single slides for indirect immunofluorescence (Euroimmun AG)
were used according to the manufacturer’s instructions. In brief,
the serumwas diluted 1:100 in PBS and incubated on the slide for
30 min at room temperature. After 5 min of washing with PBS,
50 µl detection antibodies solution (1:400 Alexa Fluor 647 goat
anti-mouse IgM [μ chain] and 1:400 Alexa Fluor 488 goat anti-
mouse IgG [H+L] in PBS) was added and incubated at room
temperature in the dark for 30min. After 5 min of washing with
PBS, the slides were covered with a cover glass and abundant
PBS was removed. Images were recorded with a Leica DMRBE
camera.
Cell purification
For coculture experiments, CD4+ T cells were isolated from the
spleens and lymph nodes of mice by negative magnetic activated
cell sorting (MACS; Miltenyi Biotech). B cells from wt littermate
mice or transgenic mice were sorted fluorescently. Primary
human CLL cells were isolated from patient peripheral blood via
Ficoll density gradient separation, and CLL cell content in pe-
ripheral blood mononuclear cells was determined by flow cy-
tometric analysis of CD5 and CD19. Samples with CLL cell
content >70% were used for experiments.
Cell stimulation and inhibitor treatment
RANKK240E-expressing or wt B cells from littermates were
stimulated with 100 ng/ml mouse recombinant RANKL (R&D
Systems), 10 µg/ml neutralizing antibody (purified mouse
α-RANKL; eBioscience), or 0.5 µM CpG (InvivoGen) for 1 to 48 h
at 37°C. Following transduction, Bal17 cells were stimulated with
100 ng/ml mouse recombinant RANKL for 5 min to 48 h at 37°C.
SP600125 was purchased from Sigma-Aldrich, and Cal-101 and
PD0325901 (PD901) from Selleckchem, and BAY70-1182 was
purchased from Caymanchem. The inhibitors were dissolved in
DMSO and used at the indicated concentrations. Murine and
human CLL cells were cultivated in coculture with murine bone
marrow–derived stromal cells (ST-2) at a ratio of 10:1 and were
treated with 10 µg/ml neutralizing antibody (purified mouse
α-RANKL; eBioscience) for 24 to 72 h. To test RANKL depen-
dency of transplanted RANKK240E-expressing CLL cells, periph-
eral blood cells derived from transplanted mice were stimulated
with mouse recombinant RANKL (R&D Systems) and subse-
quently treated with neutralizing antibody (purified mouse
α-RANKL; eBioscience) as described above and analyzed after
24 h and up to 10 d for survival via DAPI staining and flow cy-
tometric analysis.
Western blotting
Whole cell lysates were obtained using CHAPS lysis buffer, and
protein concentrations were determined by the Bradford assay.
10 µg of the samples were used for Western blotting. The blots
were probed with the following antibodies: phospho-JNK (no.
9251), phospho-AKT (no. 9275), phospho-ERK (no. 4370), β-actin
(no. 3700), and phospho-PLC-γ2 (no. 3871; all obtained from Cell
Signaling Technology).
Quantitative real-time PCR
RNA was isolated from sorted RANKK240E-expressing and wt
B cells by using RNeasy Mini Kit (QIAGEN) according to the
manufacturer’s instructions. RNA concentration of the samples
was determined by NanoDrop. RNA was reverse transcribed
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using SuperScript II (Invitrogen) according to the manu-
facturer’s instructions using a 20-µl reaction of 100 ng to 1 µg
total RNA, 0.5 mM deoxynucleotide triphosphates, 250 ng ran-
dom primers, 5 mM DTT, and 10 U/µl of SuperScriptTM II. The
generated cDNAwas used in duplicates or triplicates for RT-PCR
reactions, with primers that span exon–exon boundaries to en-
sure cDNA-specific amplification. The qPCR Core Kit for SYBR
Green I (Roche) was used to perform RT-PCR. Gene expression
patterns were normalized to the housekeeping gene, Actin. The
reaction was performed in a Light Cycler 480 II (Roche) and
analyzed for quality using melting curves.
Murine CLL model and anti-RANKL treatment
A total of 2 × 107 diseased TCL1 transgenic splenocytes were
intravenously injected into 10 female C57BL/6 mice (6–12 wk
old; purchased from Janvier Labs). Tumor growth was moni-
tored in the peripheral blood via flow cytometric analysis of
CD19 and CD5. Upon detection of a CLL population, mice were
randomized into a treatment and a control group, and the mice
were treated intraperitoneally with 5 mg/kg anti-RANKL anti-
body (eBioscience) or PBS three times a week, respectively.
After 4 wk, all mice were sacrificed, and secondary lymphoid
organs were analyzed for CLL cell content.
Patient samples
Primary CLL samples were obtained from the peripheral blood
of patients at the National Center for Tumor Diseases, Heidel-
berg, Germany. Data for IGVH status, ZAP70 expression, and
time to first treatment were taken from the clinical records. The
local ethics committee of the Faculty of Medicine, Technical
University Munich, approved patient sampling, and all patients
gave informed consent.
Tumor xenograft model
MEC-1 cells (DSMZ Cat# ACC-497, RRID: CVCL_1870; 2 × 106)
were injected intravenously into NSGmice (8–12 wk old, female,
n = 5 per group; purchased from Jackson Laboratory). On day 8
after transplantation, the mice were separated into two groups
and received 5 mg/kg anti-RANKL or PBS twice per week (i.p.).
Themice were sacrificed upon clear signs of disease according to
the animal protocol guidelines.
RANKK240E CLL cell transplantation
Splenocytes (2 × 107) of RANKK240E CD19-Cre mice (>12 mo of age,
containing >20% GFP+CD5+CD19+ cells) were transplanted into
C57BL/6 recipients (purchased from Janvier Labs). Cell out-
growth was followed via flow cytometric analysis of CD19/CD5
and GFP in peripheral blood cells.
Online supplemental material
Fig. S1 shows the strategy for the generation of RANKK240E
transgenic mice and confirmation of transgene and GFP reporter
expression in B cells. Fig. S2 demonstrates comparable devel-
opment of bone marrow, marginal, and follicular B cell subsets
as well as splenic T cell subsets in RANKK240E CD19-Cre mice and
littermate controls. Fig. S3 shows RANKL expression detected by
flow cytometry of immune and stromal cells, the effects of
MAPK, NF-κB, PI3K, and JNK inhibitors on RANKK240E-mediated
B cells survival and the expression of B cell activation markers
CD86 and MHCII. Table S1 provides the CLL patients’ charac-
teristics for the samples analyzed in this study, including their
mutational status, sex, age at diagnosis, and the patients’ overall
survival, as well as RANK (TNFRSF11A) and RANKL (TNFSF11A)
mRNA expression levels.
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Figure S1. Generation of RANKK240E-expressing mice. (A) RANKK240E targeting strategy. NEO, neomycin; pA, poly(A); SA, splice acceptor; (B) Southern blot
analysis is shown. Lanes 1 and 2 show genomic DNA from wt and transgenic mice. The size of the fragment showing the wt ROSA26 locus is 4.6 kb, the
recombined locus is 9.2 kb, and Cre-mediated removal of the STOP cassette results in an 8.7-kb fragment. (C) GFP and surface RANK expression in B cells in the
spleens of 2-mo-old RANKK240E CD19-Cre and wtmice, as analyzed by flow cytometry. The cells were pregated on CD19. Representative of three mice analyzed in
three independent experiments. (D)Western blot analysis of MACS-purified B cells shows overexpression of RANKK240E in transgenic B cells, representative for
two independent experiments.
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Figure S2. Analysis of 2–6-mo-old RANKK240E CD19-Cre and control mice. (A) The bone marrow of RANKK240E CD19-Cre (n = 7) and control littermates (n = 7)
was analyzed for B cell developmental stages in at least three independent experiments. Pro– (B220+ IgM− cKit+ CD25−), pre– (B220+ IgM− cKit− CD25+),
immature (imm; B220+ IgM+), and recirculating (recirc; B220hi IgM+) B cells are summarized, and the quantification of relative and absolute values is shown
(left), as is a representative FACS plot (right). (B) The splenocytes of RANKK240E CD19-Cre (n ≥ 7) and control littermates (n ≥ 7) were analyzed for marginal zone
(MZ) and follicular (FO) B cell content in at least three independent experiments. The quantification of relative and absolute values is shown, as is a rep-
resentative FACS plot. (C) Splenocytes were analyzed for T cell subsets of RANKK240E CD19-Cre (n ≥ 7) and control littermates (n ≥ 7), analyzed in at least three
independent experiments as depicted in the representative FACS plot (right) and quantified in the dot plot graph (left). For statistical analysis, Student’s t test
was performed. *, P < 0.05.
Alankus et al. Journal of Experimental Medicine S2













































































Table S1 is provided as aWord document and gives the CLL patients’ characteristics for the samples analyzed in this study, including
their mutational status, sex, age at diagnosis, and the patients’ overall survival, as well as RANK (TNFRSF11A) and RANKL
(TNFSF11A) mRNA expression levels.
Figure S3. RANKL expression and RANKK240E survival pathway analysis. (A and B) Flow cytometric analysis of bone marrow (A) and spleen (B) revealed
high expression levels of RANKL on CD4+ T cells and no/low expression on CD8+ T cells (n = 5), CD19+ B cells (n = 5), CD11b+ myeloid cells (n = 2), CD45−
nonhematopoietic cells (n = 5), and CD45−CD31+ endothelial cells (n = 5), analyzed in two independent experiments. (C) Pharmacological inhibition of the MAPK
pathway with PD901 and the NF-κB pathway with BAY11-7082 24 h after stimulation with RANKL led to minor changes in cell survival in RANKK240E-expressing
B cells. Inhibition of the JNK pathway with SP600125 and the PI3K pathway with Cal-101 was included as a positive control (representative for n = 3 mice,
analyzed in two independent experiments). (D) GFP+ B cells from RANKK240E transgenic mice were FACS-sorted and treated with the indicated inhibitor for
30 min before adding recombinant RANKL. After 24 h, surface marker expression was analyzed. A representative FACS blot for n = 3 mice is shown, analyzed in
two independent experiments (left). In addition, the MFI values of CD86 expression and MHCII expression upon treatment with RANKL with and without
inhibitor cotreatment is shown, representative for n = 3, analyzed in two independent experiments.
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